Jeff Aronin is a well-respected entrepreneur in the biotechnology and healthcare industry. Since 2010, he has served as the CEO and Chairman of Paragon Biosciences, an international healthcare development and biopharmaceutical investment company. Jeff is harnessing two decade’s worth of experience and expertise in growing an incubator and investor for biotech companies.
At the beginning of his career, Jeff Aronin worked closely with a physician who was treating his son suffering from seizures. Contrary to what most doctors would recommend, the physician opted for prescription drugs rather than put his son through a string of surgeries. This profound experience nurtured in him a passion for useful pharmaceuticals that alleviate suffering and subsequently save people’s lives.
At the turn of the millennium, Jeff reckoned that he had gained a breadth of knowledge in the world of biopharmaceuticals and he decided to launch Ovation Pharmaceuticals Inc. His company was built on the premise of comprehending patients’ needs, harnessing the power of science and then pushing to get drugs approved. Over the next few years, the business grew exponentially and garnered the attention of Lundbeck which acquired it for a whopping $900 million in 2009.
Fast-forward to present day, Jeff Aronin has cemented his place in the biotech industry particularly for his knack for patient-centric drug development for managing rare ailments. Under his leadership, the company has achieved monumental success with over 13 drugs approved so far and there is more to come.
In addition to personal success, Jeff Aronin wishes to extend his expertise and financial access through MATTER. This is an incubator that he founded and is presently supporting over 200 biotech startups. Paragon aims to establish a slew of biotech companies that are devoted to addressing the unmet needs of patients who are suffering from rare diseases. A few notable ones include Harmony Biosciences, Precision BP, and Castle Creek Pharmaceutical. Paragon engages the best researchers in the field who must also have an interest in entrepreneurship.
Accelerating breakthrough science and developing drugs that bring some form of reprieve to patients and prolonging their lives is very important to Jeff Aronin. Besides hunting down the next break-out star of biotech, Jeff is keen on engaging in philanthropic causes in medicine.